Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ryanodex for Exertional Heat Stroke
NCT03600376Phase 3Completed
- Sponsor
- Eagle Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Aug 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dantrolene in exertional heat stroke (EHS), sponsored by Eagle Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
dantrolene
03
Conditions
exertional heat stroke (EHS)
Beyond the preview
Go deeper on NCT03600376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600376.